The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study
Mathew Vithayathil, Giulia Francesca Manfredi, Antonio D’Alessio, Claudia Angela Maria Fulgenzi et autres
BACKGROUND: Combination immune checkpoint inhibitors are recommended as first-line therapy for advanced hepatocellular carcinoma. However, only a third of patients respond to treatment, and improved approaches to predict response are required. Using baseline clinical data, we aimed to use advanced machine learning …
gb, it, es, de, jp, at, us, tw, ca, kr (code pays fourni par la source)
3 citations
The Lancet Digital Health